icon-folder.gif   Conference Reports for NATAP  
 
  63rd Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 9-12 2012
Back grey_arrow_rt.gif
 
 
 
Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine and ribavirin with or without peginterferon alfa-2a (40KD) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study
 
 
  Reported by Jules Levin
AASLD 2012 Nov 9-13 Boston
 
J.J. Feld, I.M. Jacobson, D.M. Jensen, G.R. Foster, S. Pol, E. Tam, H. Berak, J.M. Vierling, J.A. Tavel, M.T. Navarro, S. Shahdad, R. Kulkarni, S. Le Pogam, I. Najera, C.Y. Lim, N.S. Shulman, E.S. Yetzer
 
from Jules: Roche has ongoing the Annapurna Study which looks at 4 orals: PI, non-nuc polymerase, nuc, rbv
http://www.natap.org/2012/HCV/090412_01.htm

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif

AASLD12.gif

AASLD13.gif